x

Posted 10 August, 2023

Senti Biosciences, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:SNTI in a 8-K filed on 10 August, 2023.


  On August 7, 2023, Philip Lee, Ph.D., the Company's Chief Technology Officer, notified the Company of his resignation as an employee and as Chief Technology Officer of the Company, effective on August 7, 2023, to join GeneFab as its Chief Executive Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Senti Biosciences, Inc.
Health Care/Life Sciences • Biotechnology
Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.
Market Cap
$15.3M
View Company Details
Senti Biosciences, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b)


On August 7, 2023, Philip Lee, Ph.D., the Company's Chief Technology Officer, notified the Company of his resignation as an employee and as Chief Technology Officer of the Company, effective on August 7, 2023, to join GeneFab as its Chief Executive Officer. Dr. Lee's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.